T1D Exchange Appoints Two New Members to its Board of Directors - T1D Exchange

T1D Exchange announced today the appointments of Dr. Margarita Ochoa-Maya
and Dr. Kevin Larsen to its Board of Directors. Their extensive combination of clinical care, healthcare data, and industry research experience will help to further support the organization’s commitment to advance type 1 diabetes (T1D) care and outcomes by driving collaborative change.

“We are delighted to welcome Margarita and Kevin to the T1D Exchange Board,” said Board Chair, Jay Mohr. “Their healthcare expertise and experience working in data and research will be beneficial to our Board as we continue to execute our mission of improving outcomes for all people living with T1D.”

“Margarita and Kevin bring both healthcare provider and industry perspectives,” said T1D Exchange CEO Dave Walton. “Margarita’s work as an endocrinologist and CDE and her first-hand knowledge of the provider and the patient experience, including issues specific to the Latino T1D community, are extremely valuable. Kevin’s expertise in healthcare data and clinical quality improvement, and experience with T1D professionally and personally through his brother, provides a complementary perspective to our efforts with real-world and clinic-derived data to drive research and innovation. We are excited to work with them to accelerate real-world impacts and better diabetes population health management.”

About Dr. Margarita Ochoa-Maya

Margarita has a unique combination of private practice and industry experience in the diabetes arena. She is currently serving as the Head of US Medical Affairs in Patient Value & Innovation for Biocon, an Indian biopharmaceutical firm that manufacturers biosimilar insulins among its product portfolio. Prior to Biocon, Margarita worked at Nova Biomedical as the North American Medical Director of their novel CGM program, and at Novo Nordisk as a Scientific Medical Liaison in Diabetes. She is an endocrinologist and CDE, with 15 years of experience in private practice. During that time, she maintained a significant focus on the use of technology including CGM use to improve outcomes and addressing diabetes-specific issues for the Latino community. Margarita obtained her MD from Instituto de Ciencias de la Salud in Colombia, followed by her residency at Boston University and Fellowship at Harvard Medical School.

About Dr. Kevin Larsen

Kevin is an accomplished healthcare informatics, data and clinical quality improvement expert, having worked in various roles in industry, government, and private practice. Kevin is currently serving as the Senior VP of Clinical Innovation and Translation at Optum Labs. In this role, he is involved in Optum-wide condition-specific initiatives, including one focused on Type 1 diabetes. Prior to Optum, Kevin worked at CMS and the Office of National Coordinator for Health IT where he was involved in clinical quality measure development and use of EMR data to improve quality of care. Kevin received his MD from the University of Minnesota with a focus in Internal Medicine, and a BA in Biology & Chemistry from Concordia College.

About T1D Exchange

T1D Exchange is a leader in harnessing data to advance type 1 diabetes (T1D) care and outcomes by driving collaborative change. Through real-world evidence and clinical data collection and analysis, our novel insights are identifying gaps in data and redefining best practices to improve the lives of those living with T1D. T1D Exchange actively supports quality improvement and innovation through its Quality Improvement Collaborative, patient registry, and data-oriented research services. Through a knowledge–sharing and collaboration-focused approach, T1D Exchange is accelerating real-world impacts by providing clinicians, researchers, industry partners, and advocates with the resources and services they need for better decision support and population health management. A non-profit organization, T1D Exchange was established in 2010 with ongoing support from The Leona M. and Harry B. Helmsley Charitable Trust.